Connect with us

NEWS

Cigarette Smoke Primes Lung Stem Cells for Two Cancers

Johns Hopkins scientists showed smoke first reprograms lung stem cells, so KRAS and TP53 mutations can start two different cancers.

Published

on

Cigarette smoke rewrote lung stem cells for six months before KRAS or TP53 mutations could start tumors, Johns Hopkins scientists reported on October 5, 2026. Smoke exposure alone grew no tumors, and neither did those genetic hits in clean tissue. Tumors formed only when both insults were stacked, and each mutation then selected a different stem-cell path and a different form of non-small cell lung cancer.

That order is the part most clinic talk still skips. Smoking is already tied to most lung cancer deaths. The new work maps a step that sits before a nodule, when the lung’s repair cells have been chemically retuned and the famous drivers can finally take hold.

Smoke Remade the Stem Cells First

Oncology instructor Michelle Vaz and colleagues at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center grew lung organoids, tiny 3D cultures that hold several living cell types, from normal mouse lung. They followed changes in lung cells over six months of cigarette smoke condensate, the chemical mix carried in smoke, and checked early changes in organoids made from normal human lung.

Vaz said the point was to watch cancer from the first molecular turns, not from a formed mass. The cultures are rich in the stem cells that rebuild airways and air sacs, so the team could track more than one repair pool as the smoke chemicals stayed on.

THE SIX-MONTH PROTOCOL

  1. Start: Organoids are grown from normal mouse lung, with key early readouts repeated in human lung cultures.
  2. Weekly feeding: Cultures are split on a regular cycle and given fresh smoke condensate, while control cultures get the solvent alone.
  3. Months of drift: DNA methylation tags shift, packed DNA opens or closes in new patterns, and genes for inflammation, immune signaling, and programmed cell death lose activity, including ZBP1.
  4. At six months: Mutant KRAS is added, or TP53 is knocked out, in both smoke-conditioned and clean organoids, which are then placed into mice.
  5. Readout: Tumors appear only from smoke-conditioned organoids that also carry one of those two genetic hits.

Over those months the mix of cell types inside the organoids changed. Exposed cells picked up traits of a precancerous, tumor-friendly state, Vaz’s group found, before anyone added a classic driver gene. Co-senior author Stephen Baylin, a cancer researcher at Johns Hopkins, has long argued that chemical tags on DNA can ready a cell for transformation; this model puts that claim inside a stem-cell-rich lung.

Two Stem Cell States and Two Cancers

The paper on distinct stem cell states driving NSCLC subtypes is blunt about what happened after the mutations went in. The investigators did not aim KRAS or TP53 loss at a chosen cell type. Each alteration appeared to select, from a mixed population, the stem-cell state in which it could live.

WHAT EACH DRIVER PRODUCED

Insult addedStem cells that took overCancer that grew in mice
Smoke condensate onlyAltered stem-cell mix, no driverNo tumors
Mutant KRAS or TP53 loss, no smokeUnconditioned organoidsNo tumors
Smoke plus mutant KRASBronchioalveolar stem cells, at the airway-air sac junctionPoorly differentiated adenocarcinoma
Smoke plus TP53 lossBasal stem cells that line and repair airwaysSquamous cell carcinoma

Single-cell RNA sequencing traced the KRAS tumors to an altered state derived from bronchioalveolar stem cells, which sit where airways meet the alveoli. The TP53-deficient tumors traced to basal stem cells, the reserve lining of the passages that carry air. Vaz said each mutation seemed to select for a particular stem-cell state, and that the team had not engineered the event into a chosen cell type.

That pairing matches how human lung cancer is already sorted in the clinic. Adenocarcinoma is the glandular tumor that often starts farther out in the lung. Squamous cell carcinoma more often tracks the central airways. KRAS alterations cluster in the first group and are scarce in the second, which is why a smoke-built neighborhood is not a footnote. It is a fork.

Why Healthy Lungs Can Carry Driver Mutations

Oncologists have known for years that KRAS and TP53 damage can sit in tissue that is not yet cancer. Healthy or precancerous airway lining sometimes carries the same hits that textbooks call drivers. If a mutation were a match, those patches would all become tumors. They do not.

What this tells us is that the genetic event alone is not sufficient.

Michelle Vaz, oncology instructor, Johns Hopkins Medicine news release

Vaz and Baylin stress that the cells first need the chronic smoke changes, which then make them open to transformation by these mutations. In the organoids, inflammatory and immune pathways were turned down, as were genes that run programmed cell death. ZBP1, a regulator of inflammatory cell death, was among the genes pushed quiet, and that silencing was strongest in the KRAS-mutant tumors.

Human lung adenocarcinoma datasets showed the same tilt: ZBP1 and related interferon-pathway genes ran lower in KRAS-mutant tumors than in TP53-mutant tumors. The human numbers are correlative, not a replay of the mouse implant, but they keep the lab result from floating free of patient tissue.

The useful clinical reading is a window that exists before a scan shows a mass, when repair cells have already been retuned and a later KRAS or TP53 hit has somewhere to land. Screening still looks for nodules. This work is about the soil those nodules grow in.

The Risk That Outlasts the Last Cigarette

If smoke’s lasting product is a cell state, not only a mutation count, then putting the pack down does not instantly restore the old neighborhood. That is already visible in people, even though this organoid study did not follow quitters.

The International Agency for Research on Cancer says lung cancer was the world’s most common cancer and the leading cause of cancer death in 2024, with almost 2.65 million people diagnosed and more than 1.8 million deaths. Tobacco smoking remains responsible for approximately 85% of all cases, and the disease causes more than twice as many deaths as colorectal cancer. IARC marked Lung Cancer Awareness Month on November 2, 2026, with those figures still on the table.

Quitting still cuts risk. It does not reset it to the never-smoked baseline on a calendar date. Carolyn Baglole, a pharmacology professor at McGill University, put the gap in plain terms after her group reanalyzed public single-cell data: current smokers carry the highest risk, but former smokers still sit above people who never smoked, and some molecular changes persist long after the last cigarette.

WHAT APPEARS TO LINGER AFTER QUITTING

  • Some cells recover: McGill’s analysis of more than 100,000 lung cells from 21 people (nine who never smoked, five current smokers, seven former smokers) found certain cell types eased back after quitting.
  • Others keep a mark: Lasting shifts remained in genes tied to tissue structure, immune function, and blood vessel health, and some former smokers showed patterns seen in neither current smokers nor never-smokers.
  • Airway versus air sac: Earlier sequencing of bronchial cells found a low-mutation stem-cell pool that expands after people quit, a pattern that fits the faster drop in squamous risk, while alveolar progenitor genomes have been reported to keep a high mutation load, which fits adenocarcinoma that does not fall as fast.
  • The long tail: An American Cancer Society systematic review found lung cancer risk in people with a 20-plus pack-year history can stay elevated for 2 or 3 decades compared with never-smokers, even as it declines slowly.

Baglole said some damage looks reversible and other changes persist. That split is what the Hopkins map makes mechanistic. Basal cells that line airways can, in other studies, be partly replaced by a quieter stem-cell pool once smoke is gone. Bronchioalveolar and alveolar repair cells look harder to overwrite. KRAS-driven adenocarcinoma lives in that second neighborhood.

Screening Rules Still Split on 15 Years

U.S. screening policy still treats time since the last cigarette as a cliff, or it does not, depending on which rule a clinic follows. The U.S. Preventive Services Task Force’s 2021 statement, a B recommendation, calls for yearly low-dose CT in adults aged 50 to 80 who have a 20 pack-year history and currently smoke or have quit smoking within the last 15 years. Screening is supposed to stop once a person has not smoked for 15 years, or if another illness makes curative treatment unrealistic.

The American Cancer Society’s 2023 update kept the same age band and the same 20 pack-year floor and then dropped the quit clock. On the society’s own guideline page, years since quitting is no longer a qualifier for starting or stopping yearly scans in people who used to smoke and still meet the pack-year and age tests.

WHO THE TWO U.S. RULES STILL COVER

RuleAgeSmoking historyYears since quit
USPSTF 202150 to 8020 pack-years or moreCurrent, or 15 or fewer
ACS 202350 to 8020 pack-years or moreNo cutoff

The ACS change was built on evidence that incidence stays high past the 15-year line, even as it eases, and that people who remain eligible under USPSTF can age out of coverage while their adenocarcinoma risk is still climbing with age. Medicare and many insurers still track the Task Force clock, so a former heavy smoker 16 years out can be in one guideline and out of the other.

The Hopkins organoids do not settle that policy fight. They do give it a cell address. If squamous risk falls because basal lineages can be rebuilt, a 15-year stop may match one disease and miss the other. If KRAS-ready bronchioalveolar states are stickier, the cancer that screening most needs to catch in long-quit patients is the one this model grew from smoke plus KRAS.

Limits of a Six-Month Smoke Model

The principal system used mouse organoids bathed in condensate, not lungs drawing real smoke, and tumors were scored after the cells were placed into mice. Only two driver alterations were tested. Human support was limited to early organoid changes and a retrospective look at gene expression in adenocarcinoma. The authors present a mechanistic frame, not a clinical test.

WHAT WE KNOW

  • The double hit: In this model, smoke, epigenetic remodeling, and a driver mutation were each insufficient on their own.
  • The fork: KRAS and TP53 loss selected different stem-cell states and different NSCLC subtypes without being aimed at a cell type.
  • A death-gene tilt: ZBP1 and interferon signaling were especially quiet in KRAS-mutant tumors, in the organoids and in human adenocarcinoma data.

WHAT IS UNCONFIRMED

  • Inhaled smoke: Condensate in a dish is not a pack-a-day airway, and the time scale is compressed.
  • Other drivers: EGFR, ALK, and the rest of the NSCLC map were not added, so the neighborhood rule is proven only for KRAS and TP53 loss.
  • A clinic marker: The altered stem-cell states are not yet a blood test, a scan sign, or a drug target in people.

Vaz’s next question is whether some of those silenced cell-death paths can be aimed, in the KRAS setting versus the TP53 setting, and whether epigenetic therapy or immunotherapy could be paired with that work in tumors that now shrug off treatment. She also wants a closer look at the gene-tag changes inside each stem-cell state. Additional checks are required, the team says, before those states can mark people at rising risk or guide prevention.

Until then the finding is narrower and still hard to ignore. Six months of smoke did not make cancer by itself. It built two neighborhoods in which a later KRAS or TP53 hit could, and the cancer that grew depended on which neighborhood the mutation found.

Frequently Asked Questions

What Is a Pack-Year in Lung Screening?

A pack-year equals about 20 cigarettes a day for one year. Smoking two packs a day for 10 years also totals 20 pack-years, the floor both U.S. screening guidelines now use for yearly low-dose CT in adults aged 50 to 80.

What Cancers Fall Under Non-Small Cell Lung Cancer?

Non-small cell lung cancer groups adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, which together are the usual adult lung cancers. Small-cell lung cancer is a separate, faster-spreading disease, and the Johns Hopkins organoids did not model it.

How Common Is KRAS in Adenocarcinoma Versus Squamous Tumors?

In a large NSCLC genomic series that counted 4,706 KRAS-mutant samples, KRAS mutations were found in 37.2% of adenocarcinomas and only 4.4% of squamous cell carcinomas, with G12C the most common KRAS subtype at 40% of those mutations.

Can Never-Smokers Carry KRAS Lung Tumors?

Yes. In one 482-tumor adenocarcinoma series, KRAS mutations appeared in 15% of never-smokers (12 of 81), 22% of former smokers, and 25% of current smokers, so the gene is enriched with smoking but not exclusive to it.

Did the Study Use Inhaled Cigarette Smoke?

No. The team used cigarette smoke condensate from Murthy Pharmaceuticals at 10 and 20 micrograms per milliliter on four independent organoid lines that were split every 7 days, a concentrated chemical extract rather than smoke drawn through living airways.

Disclaimer: This article is news reporting and analysis of a laboratory study and of published screening rules. It is informational only and is not medical advice, a diagnosis, a screening order, or a recommendation to start, stop, or change any test or treatment. Readers should talk with a qualified physician or oncologist, and with the clinic that handles lung screening in their health system, before making decisions about smoking cessation aids, CT screening, or cancer care. Case counts, mutation rates, and eligibility rules reflect the named sources as they stood on the dates cited and can change as guidelines and evidence are updated.

Harry is the editor of NEWS ANALYSIS. He writes across the publication's ten desks, with most of his time going to the stories where a number, a filing or a study decides the argument. His working rule is simple: read the source document before writing about it, and tell the reader plainly which parts are established and which are somebody's claim. He is responsible for the standards set out on this site's Editorial Standards and Fact Checking pages, and for correcting the record openly when the publication gets something wrong.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending